Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Trachoma | 4 | 2018 | 48 | 1.92 | Why? |
| HIV-1 | 14 | 2019 | 3365 | 1.31 | Why? |
| HIV Infections | 32 | 2020 | 11620 | 1.27 | Why? |
| Chlamydia trachomatis | 3 | 2018 | 172 | 0.93 | Why? |
| HIV Antibodies | 5 | 2019 | 776 | 0.84 | Why? |
| HIV | 5 | 2019 | 1116 | 0.77 | Why? |
| Circumcision, Male | 5 | 2017 | 57 | 0.69 | Why? |
| Uganda | 13 | 2021 | 1057 | 0.66 | Why? |
| Models, Immunological | 1 | 2021 | 727 | 0.59 | Why? |
| Antigens, Bacterial | 1 | 2018 | 330 | 0.57 | Why? |
| Convalescence | 4 | 2021 | 2829 | 0.54 | Why? |
| Antibodies, Bacterial | 1 | 2018 | 510 | 0.53 | Why? |
| Superinfection | 5 | 2019 | 459 | 0.53 | Why? |
| Herpes Genitalis | 2 | 2011 | 90 | 0.53 | Why? |
| AIDS Dementia Complex | 1 | 2014 | 48 | 0.52 | Why? |
| Endemic Diseases | 3 | 2021 | 480 | 0.49 | Why? |
| Simplexvirus | 1 | 2011 | 124 | 0.43 | Why? |
| Homosexuality, Male | 2 | 2018 | 1158 | 0.41 | Why? |
| HIV Seropositivity | 3 | 2019 | 320 | 0.40 | Why? |
| Azithromycin | 3 | 2017 | 3943 | 0.40 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.37 | Why? |
| Immune Tolerance | 1 | 2014 | 608 | 0.37 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.37 | Why? |
| AIDS Serodiagnosis | 2 | 2018 | 64 | 0.34 | Why? |
| Mass Screening | 2 | 2018 | 8005 | 0.34 | Why? |
| Sexually Transmitted Diseases | 2 | 2018 | 694 | 0.33 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2021 | 5837 | 0.32 | Why? |
| Virus Latency | 2 | 2018 | 251 | 0.31 | Why? |
| Tanzania | 3 | 2018 | 294 | 0.30 | Why? |
| Trichomonas Infections | 2 | 2018 | 24 | 0.29 | Why? |
| Genetic Variation | 3 | 2018 | 3919 | 0.29 | Why? |
| Antibodies, Neutralizing | 10 | 2021 | 25288 | 0.29 | Why? |
| Anti-Retroviral Agents | 3 | 2018 | 1099 | 0.29 | Why? |
| Antibody Affinity | 3 | 2020 | 1078 | 0.28 | Why? |
| Anti-Bacterial Agents | 3 | 2017 | 10083 | 0.27 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 3 | 2021 | 349 | 0.26 | Why? |
| Viral Load | 12 | 2020 | 15850 | 0.26 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4545 | 0.25 | Why? |
| Sexual Behavior | 5 | 2018 | 1322 | 0.25 | Why? |
| Receptors, Interleukin-7 | 1 | 2019 | 8 | 0.21 | Why? |
| Ikaros Transcription Factor | 1 | 2019 | 10 | 0.21 | Why? |
| Anti-HIV Agents | 4 | 2020 | 2209 | 0.19 | Why? |
| Disease Progression | 4 | 2019 | 13580 | 0.19 | Why? |
| Chlamydia Infections | 2 | 2018 | 248 | 0.18 | Why? |
| Travel | 1 | 2017 | 7220 | 0.18 | Why? |
| Urogenital System | 1 | 2018 | 49 | 0.18 | Why? |
| Bacteria | 1 | 2009 | 1897 | 0.17 | Why? |
| Male | 41 | 2021 | 367725 | 0.17 | Why? |
| Hepatitis Antibodies | 1 | 2018 | 100 | 0.17 | Why? |
| Motivational Interviewing | 1 | 2017 | 55 | 0.17 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.17 | Why? |
| Immune Sera | 2 | 2021 | 884 | 0.17 | Why? |
| Cluster Analysis | 2 | 2017 | 3001 | 0.16 | Why? |
| Penis | 1 | 2017 | 101 | 0.16 | Why? |
| Female | 39 | 2021 | 380317 | 0.16 | Why? |
| Receptors, IgG | 1 | 2019 | 578 | 0.15 | Why? |
| Antibodies, Viral | 9 | 2021 | 51949 | 0.15 | Why? |
| Hepatitis C Antibodies | 1 | 2016 | 120 | 0.15 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.14 | Why? |
| HLA Antigens | 1 | 2021 | 830 | 0.14 | Why? |
| CD4 Lymphocyte Count | 5 | 2020 | 1517 | 0.14 | Why? |
| Syphilis | 1 | 2018 | 318 | 0.13 | Why? |
| Hepatitis E virus | 1 | 2018 | 306 | 0.13 | Why? |
| South Africa | 3 | 2019 | 3326 | 0.13 | Why? |
| Phylogeny | 4 | 2019 | 13341 | 0.13 | Why? |
| Adult | 27 | 2021 | 244371 | 0.13 | Why? |
| Molecular Epidemiology | 1 | 2019 | 1638 | 0.13 | Why? |
| Immunoglobulin G | 6 | 2021 | 21571 | 0.13 | Why? |
| Humans | 53 | 2021 | 930598 | 0.13 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.13 | Why? |
| Hepatitis E | 1 | 2018 | 319 | 0.13 | Why? |
| Prevalence | 9 | 2021 | 25773 | 0.13 | Why? |
| Antibody Formation | 4 | 2021 | 4038 | 0.13 | Why? |
| Heterosexuality | 3 | 2019 | 148 | 0.12 | Why? |
| Longitudinal Studies | 4 | 2018 | 9893 | 0.12 | Why? |
| Blood Donors | 3 | 2021 | 2956 | 0.12 | Why? |
| Papillomaviridae | 1 | 2017 | 404 | 0.12 | Why? |
| Genotype | 3 | 2019 | 4697 | 0.12 | Why? |
| Hospitals, Urban | 1 | 2018 | 950 | 0.12 | Why? |
| Cohort Studies | 8 | 2021 | 36005 | 0.12 | Why? |
| Community Health Workers | 1 | 2017 | 468 | 0.12 | Why? |
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 3633 | 0.12 | Why? |
| Tetracycline | 1 | 2011 | 33 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2021 | 995 | 0.11 | Why? |
| Papillomavirus Infections | 2 | 2018 | 861 | 0.11 | Why? |
| Cytokines | 3 | 2017 | 15010 | 0.11 | Why? |
| Antibiotic Prophylaxis | 1 | 2014 | 399 | 0.11 | Why? |
| Denmark | 1 | 2018 | 2654 | 0.11 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 3 | 2019 | 386 | 0.11 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.11 | Why? |
| Immunity, Innate | 1 | 2009 | 6570 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.10 | Why? |
| Mobile Health Units | 1 | 2017 | 741 | 0.10 | Why? |
| Prospective Studies | 6 | 2019 | 43301 | 0.10 | Why? |
| Young Adult | 16 | 2021 | 93724 | 0.10 | Why? |
| Emergency Service, Hospital | 3 | 2021 | 14232 | 0.10 | Why? |
| Receptors, CCR5 | 1 | 2011 | 186 | 0.10 | Why? |
| Eye | 1 | 2014 | 374 | 0.10 | Why? |
| Hepacivirus | 2 | 2017 | 1509 | 0.10 | Why? |
| Adolescent | 14 | 2021 | 86841 | 0.10 | Why? |
| Vaginosis, Bacterial | 1 | 2010 | 51 | 0.10 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.10 | Why? |
| Infant | 4 | 2018 | 30274 | 0.10 | Why? |
| Diagnostic Tests, Routine | 2 | 2020 | 2643 | 0.10 | Why? |
| HIV Envelope Protein gp120 | 1 | 2011 | 267 | 0.09 | Why? |
| Selection, Genetic | 1 | 2012 | 691 | 0.09 | Why? |
| Child, Preschool | 4 | 2018 | 36283 | 0.09 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.09 | Why? |
| Biological Transport | 1 | 2009 | 290 | 0.09 | Why? |
| Solubility | 1 | 2009 | 382 | 0.09 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.09 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.08 | Why? |
| Immunoassay | 3 | 2021 | 4485 | 0.08 | Why? |
| Disease Transmission, Infectious | 3 | 2019 | 9044 | 0.08 | Why? |
| Lipopolysaccharide Receptors | 1 | 2009 | 357 | 0.08 | Why? |
| Ambulatory Care Facilities | 1 | 2018 | 2063 | 0.08 | Why? |
| Antibody Specificity | 2 | 2021 | 1328 | 0.08 | Why? |
| Secondary Prevention | 1 | 2011 | 762 | 0.08 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.08 | Why? |
| Family Health | 1 | 2011 | 731 | 0.08 | Why? |
| Cameroon | 2 | 2017 | 464 | 0.08 | Why? |
| Self Report | 1 | 2018 | 3802 | 0.07 | Why? |
| Immunity | 1 | 2017 | 2651 | 0.07 | Why? |
| Immunization, Passive | 4 | 2021 | 10067 | 0.07 | Why? |
| Lipopolysaccharides | 1 | 2009 | 848 | 0.07 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.06 | Why? |
| Sequence Analysis, DNA | 1 | 2012 | 2830 | 0.06 | Why? |
| Population Surveillance | 2 | 2017 | 4967 | 0.06 | Why? |
| Child | 4 | 2018 | 70012 | 0.06 | Why? |
| Biomarkers | 4 | 2017 | 23361 | 0.06 | Why? |
| Health Care Rationing | 1 | 2017 | 2558 | 0.06 | Why? |
| Inflammation Mediators | 2 | 2017 | 2654 | 0.06 | Why? |
| Linear Models | 2 | 2020 | 1914 | 0.06 | Why? |
| Sexual Partners | 2 | 2017 | 612 | 0.06 | Why? |
| Cross-Sectional Studies | 9 | 2021 | 53120 | 0.06 | Why? |
| Polymerase Chain Reaction | 2 | 2017 | 6740 | 0.06 | Why? |
| Biophysical Phenomena | 1 | 2021 | 78 | 0.06 | Why? |
| Age Distribution | 1 | 2011 | 3567 | 0.06 | Why? |
| Neutralization Tests | 3 | 2021 | 6698 | 0.05 | Why? |
| Virus Shedding | 1 | 2017 | 5834 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Africa | 1 | 2009 | 2986 | 0.05 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.05 | Why? |
| Communicable Diseases | 1 | 2014 | 2148 | 0.05 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.05 | Why? |
| Barbados | 1 | 2018 | 5 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2019 | 5397 | 0.05 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.05 | Why? |
| Phagocytosis | 1 | 2021 | 409 | 0.05 | Why? |
| Trichomonas vaginalis | 1 | 2018 | 19 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.05 | Why? |
| CD4-CD8 Ratio | 1 | 2019 | 235 | 0.05 | Why? |
| HIV Seroprevalence | 1 | 2017 | 16 | 0.05 | Why? |
| Immunoenzyme Techniques | 1 | 2021 | 448 | 0.05 | Why? |
| Bacterial Outer Membrane Proteins | 1 | 2018 | 60 | 0.05 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 39 | 0.04 | Why? |
| Incidence | 5 | 2017 | 25622 | 0.04 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
| Sex Factors | 3 | 2020 | 11014 | 0.04 | Why? |
| RNA, Viral | 2 | 2017 | 32276 | 0.04 | Why? |
| Molecular Diagnostic Techniques | 1 | 2013 | 4239 | 0.04 | Why? |
| HIV Seronegativity | 1 | 2017 | 112 | 0.04 | Why? |
| Nutrition Surveys | 1 | 2018 | 287 | 0.04 | Why? |
| Species Specificity | 1 | 2021 | 1356 | 0.04 | Why? |
| United States | 5 | 2021 | 46150 | 0.04 | Why? |
| Poisson Distribution | 1 | 2017 | 348 | 0.04 | Why? |
| Graft Survival | 1 | 2019 | 587 | 0.04 | Why? |
| Community-Institutional Relations | 1 | 2017 | 164 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2021 | 813 | 0.04 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.04 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.04 | Why? |
| Community-Based Participatory Research | 1 | 2017 | 271 | 0.04 | Why? |
| Aged | 6 | 2021 | 215776 | 0.04 | Why? |
| Virus Replication | 2 | 2018 | 14331 | 0.04 | Why? |
| Societies, Scientific | 1 | 2018 | 414 | 0.03 | Why? |
| Transition Temperature | 1 | 2013 | 11 | 0.03 | Why? |
| Complement Activation | 1 | 2021 | 949 | 0.03 | Why? |
| African Americans | 2 | 2021 | 3363 | 0.03 | Why? |
| Gonorrhea | 1 | 2018 | 315 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Host-Pathogen Interactions | 2 | 2011 | 11041 | 0.03 | Why? |
| Chromatography, High Pressure Liquid | 1 | 2018 | 669 | 0.03 | Why? |
| Russia | 1 | 2018 | 989 | 0.03 | Why? |
| Risk-Taking | 1 | 2018 | 508 | 0.03 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.03 | Why? |
| Surveys and Questionnaires | 3 | 2018 | 43792 | 0.03 | Why? |
| Cell Differentiation | 1 | 2019 | 1338 | 0.03 | Why? |
| Substance Abuse, Intravenous | 1 | 2017 | 411 | 0.03 | Why? |
| Infant, Newborn | 2 | 2014 | 23105 | 0.03 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2010 | 5164 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.03 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.03 | Why? |
| Receptors, CXCR4 | 1 | 2011 | 83 | 0.03 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.03 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2017 | 1265 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| India | 2 | 2017 | 11875 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2019 | 2115 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Self Care | 1 | 2017 | 918 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2018 | 1672 | 0.02 | Why? |
| Graft Rejection | 1 | 2019 | 1766 | 0.02 | Why? |
| Bayes Theorem | 1 | 2018 | 3237 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Income | 1 | 2017 | 1564 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.02 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.02 | Why? |
| Plasma | 1 | 2018 | 1809 | 0.02 | Why? |
| Early Diagnosis | 1 | 2016 | 2443 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2019 | 3567 | 0.02 | Why? |
| Models, Molecular | 1 | 2021 | 7616 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Epitopes | 1 | 2017 | 4113 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Kidney Failure, Chronic | 1 | 2019 | 3222 | 0.02 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Proportional Hazards Models | 1 | 2011 | 6543 | 0.01 | Why? |
| Antiviral Agents | 1 | 2011 | 41703 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Algorithms | 1 | 2013 | 7346 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
Quinn's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(240)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(126)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_